Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
S.LemosF
Oral GLP-1s for obesity saw a recent setback when in April (April 2025), Pfizer announced that it was discontinuing development of danuglipron, an oral GLP-1 receptor agonist, which was being investigated for chronic weight management, due to potential liver toxicity
This tumor microenvironment-associated leptin-leptin receptor signaling contributes to the different hallmarks of cancer, ranging from inflammatory changes to metastasis
Fact Sheet for health professionals, National Institutes of Health (NIH)
10.1146/annurev.nutr.18.1.39 Annu
US$ 20.74
US$ 28.69
US$ 24.13
US$ 21.60
.png)
US$ 21.98
US$ 25.22
US$ 22.58
US$ 22.12
